Is EP Biocomposites overvalued or undervalued?

As of 10 November 2025, the valuation grade for EP Biocomposites has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE Ratio of 17.14, an EV to EBITDA of 11.50, and a Price to Book Value of 1.65. In comparison, Altius Telecom, which is rated very attractive, has a significantly higher PE Ratio of 56.22, while Sagility, rated fair, has a PE Ratio of 29.75.
The recent performance of EP Biocomposites has been notably poor, with a year-to-date stock return of -38.6%, contrasting sharply with a Sensex return of 6.91% over the same period. This underperformance further supports the conclusion that the company is overvalued relative to its peers and the broader market.